|
1
|
Dasarathy S and Merli M: Sarcopenia from
mechanism to diagnosis and treatment in liver disease. J Hepatol.
65:1232–1244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bhanji RA, Montano-Loza AJ and Watt KD:
Sarcopenia in cirrhosis: Looking beyond the skeletal muscle loss to
see the systemic disease. Hepatology. 70:2193–2203. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tandon P, Montano-Loza AJ, Lai JC,
Dasarathy S and Merli M: Sarcopenia and frailty in decompensated
cirrhosis. J Hepatol. 75(Suppl 1): S147–S162. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vasques J, Guerreiro CS, Sousa J, Pinto M
and Cortez-Pinto H: Nutritional support in cirrhotic patients with
sarcopenia. Clin Nutr ESPEN. 33:12–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ebadi M, Bhanji RA, Mazurak VC and
Montano-Loza AJ: Sarcopenia in cirrhosis: From pathogenesis to
interventions. J Gastroenterol. 54:845–859. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ascenzi F, Barberi L, Dobrowolny G, Villa
Nova Bacurau A, Nicoletti C, Rizzuto E, Rosenthal N, Scicchitano BM
and Musarò A: Effects of IGF-1 isoforms on muscle growth and
sarcopenia. Aging Cell. 18:e129542019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishikawa H, Enomoto H, Nishiguchi S and
Iijima H: Liver cirrhosis and sarcopenia from the viewpoint of
dysbiosis. Int J Mol Sci. 21:52542020. View Article : Google Scholar :
|
|
8
|
West J, Gow PJ, Testro A, Chapman B and
Sinclair M: Exercise physiology in cirrhosis and the potential
benefits of exercise interventions: A review. J Gastroenterol
Hepatol. 36:2687–2705. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dos Santos ALS and Anastácio LR: The
impact of L-branched-chain amino acids and L-leucine on
malnutrition, sarcopenia, and other outcomes in patients with
chronic liver disease. Expert Rev Gastroenterol Hepatol.
15:181–194. 2021. View Article : Google Scholar
|
|
10
|
Sinclair M, Grossmann M, Angus PW,
Hoermann R, Hey P, Scodellaro T and Gow PJ: Low testosterone as a
better predictor of mortality than sarcopenia in men with advanced
liver disease. J Gastroenterol Hepatol. 31:661–667. 2016.
View Article : Google Scholar
|
|
11
|
Ponziani FR, Picca A, Marzetti E, Calvani
R, Conta G, Del Chierico F, Capuani G, Faccia M, Fianchi F, Funaro
B, et al: Characterization of the gut-liver-muscle axis in
cirrhotic patients with sarcopenia. Liver Int. 41:1320–1334. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kendler BS: Carnitine: An overview of its
role in preventive medicine. Prev Med. 15:373–390. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Houten SM, Wanders RJA and Ranea-Robles P:
Metabolic interactions between peroxisomes and mitochondria with a
special focus on acylcarnitine metabolism. Biochim Biophys Acta Mol
Basis Dis. 1866:1657202020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hanai T, Shiraki M, Imai K, Suetugu A,
Takai K and Shimizu M: Usefulness of carnitine supplementation for
the complications of liver cirrhosis. Nutrients. 12:19152020.
View Article : Google Scholar :
|
|
15
|
Ohashi K, Ishikawa T, Hoshii A, Hokari T,
Suzuki M, Noguchi H, Hirosawa H, Koyama F, Kobayashi M, Hirosawa S,
et al: Effect of levocarnitine administration in patients with
chronic liver disease. Exp Ther Med. 20:942020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ohara M, Ogawa K, Suda G, Kimura M,
Maehara O, Shimazaki T, Suzuki K, Nakamura A, Umemura M, Izumi T,
et al: L-carnitine suppresses loss of skeletal muscle mass in
patients with liver cirrhosis. Hepatol Commun. 2:906–918. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hiramatsu A, Aikata H, Uchikawa S, Ohya K,
Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, et al:
Levocarnitine use is associated with improvement in sarcopenia in
patients with liver cirrhosis. Hepatol Commun. 3:348–355. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bass NM, Mullen KD, Sanyal A, Poordad F,
Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, et
al: Rifaximin treatment in hepatic encephalopathy. N Engl J Med.
362:1071–1081. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lyon KC, Likar E, Martello JL and Regier
M: Retrospective cross-sectional pilot study of rifaximin dosing
for the prevention of recurrent hepatic encephalopathy. J
Gastroenterol Hepatol. 32:1548–1552. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rahimi RS, Brown KA, Flamm SL and Brown RS
Jr: Overt hepatic encephalopathy: Current pharmacologic treatments
and improving clinical outcomes. Am J Med. 134:1330–1338. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumar A, Davuluri G, Silva RNE, Engelen
MPKJ, Ten Have GAM, Prayson R, Deutz NEP and Dasarathy S: Ammonia
lowering reverses sarcopenia of cirrhosis by restoring skeletal
muscle proteostasis. Hepatology. 65:2045–2058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaji K, Saikawa S, Takaya H, Fujinaga Y,
Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Tsuji Y, Sawada Y, et
al: Rifaximin alleviates endotoxemia with decreased serum levels of
soluble CD163 and mannose receptor and partial modification of gut
microbiota in cirrhotic patients. Antibiotics (Basel). 9:1452020.
View Article : Google Scholar
|
|
23
|
Fujinaga Y, Kawaratani H, Kaya D, Tsuji Y,
Ozutsumi T, Furukawa M, Kitagawa K, Sato S, Nishimura N, Sawada Y,
et al: Effective combination therapy of angiotensin-II receptor
blocker and rifaximin for hepatic fibrosis in rat model of
nonalcoholic steatohepatitis. Int J Mol Sci. 21:55892020.
View Article : Google Scholar :
|
|
24
|
Demiroren K, Dogan Y, Kocamaz H, Ozercan
IH, Ilhan S, Ustundag B and Bahcecioglu IH: Protective effects of
L-carnitine, N-acetylcysteine and genistein in an experimental
model of liver fibrosis. Clin Res Hepatol Gastroenterol. 38:63–72.
2014. View Article : Google Scholar
|
|
25
|
Horinouchi T, Hoshi A, Harada T, Higa T,
Karki S, Terada K, Higashi T, Mai Y, Nepal P, Mazaki Y and Miwa S:
Endothelin-1 suppresses insulin-stimulated Akt phosphorylation and
glucose uptake via GPCR kinase 2 in skeletal muscle cells. Br J
Pharmacol. 173:1018–1032. 2016. View Article : Google Scholar
|
|
26
|
Takeda S, Kaji K, Nishimura N, Enomoto M,
Fujimoto Y, Murata K, Takaya H, Kawaratani H, Moriya K, Namisaki T,
et al: Angiotensin receptor blockers potentiate the protective
effect of branched-chain amino acids on skeletal muscle atrophy in
cirrhotic rats. Mol Nutr Food Res. 65:e21005262021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Doyle A, Zhang G, Abdel Fattah EA, Eissa
NT and Li YP: Toll-like receptor 4 mediates
lipopolysaccharide-induced muscle catabolism via coordinate
activation of ubiquitin-proteasome and autophagy-lysosome pathways.
FASEB J. 25:99–110. 2011. View Article : Google Scholar :
|
|
28
|
Girven M, Dugdale HF, Owens DJ, Hughes DC,
Stewart CE and Sharples AP: l-Glutamine improves skeletal muscle
cell differentiation and prevents myotube atrophy after cytokine
(TNF-α) stress via reduced p38 MAPK signal transduction. J Cell
Physiol. 231:2720–2732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nishikawa H, Shiraki M, Hiramatsu A,
Moriya K, Hino K and Nishiguchi S: Japan society of hepatology
guidelines for sarcopenia in liver disease (1st edition):
Recommendation from the working group for creation of sarcopenia
assessment criteria. Hepatol Res. 46:951–963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao JH, Wen SL, Tong H, Wang CH, Yang WJ,
Tang SH, Yan ZP, Tai Y, Ye C, Liu R, et al: Inhibition of
cyclooxygenase-2 alleviates liver cirrhosis via improvement of the
dysfunctional gut-liver axis in rats. Am J Physiol Gastrointest
Liver Physiol. 310:G962–G372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
32
|
Shahini A, Rajabian N, Choudhury D,
Shahini S, Vydiam K, Nguyen T, Kulczyk J, Santarelli T, Ikhapoh I,
Zhang Y, et al: Ameliorating the hallmarks of cellular senescence
in skeletal muscle myogenic progenitors in vitro and in vivo. Sci
Adv. 7:eabe56712021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Giusto M, Barberi L, Di Sario F, Rizzuto
E, Nicoletti C, Ascenzi F, Renzi A, Caporaso N, D'Argenio G, Gaudio
E, et al: Skeletal muscle myopenia in mice model of bile duct
ligation and carbon tetrachloride-induced liver cirrhosis. Physiol
Rep. 5:e131532017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moretti A, Paoletta M, Liguori S, Bertone
M, Toro G and Iolascon G: Choline: An essential nutrient for
skeletal muscle. Nutrients. 12:21442020. View Article : Google Scholar :
|
|
35
|
Sawada Y, Kawaratani H, Kubo T, Fujinaga
Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, et al:
Combining probiotics and an angiotensin-II type 1 receptor blocker
has beneficial effects on hepatic fibrogenesis in a rat model of
non-alcoholic steatohepatitis. Hepatol Res. 49:284–295. 2019.
View Article : Google Scholar
|
|
36
|
Qiu J, Thapaliya S, Runkana A, Yang Y,
Tsien C, Mohan ML, Narayanan A, Eghtesad B, Mozdziak PE, McDonald
C, et al: Hyperammonemia in cirrhosis induces transcriptional
regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl
Acad Sci USA. 110:18162–18167. 2013. View Article : Google Scholar
|
|
37
|
Saiman Y and Serper M: Frailty and
sarcopenia in patients pre- and post-liver transplant. Clin Liver
Dis. 25:35–51. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao B and Bataller R: Alcoholic liver
disease: Pathogenesis and new therapeutic targets.
Gastroenterology. 141:1572–1585. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leung C, Rivera L, Furness JB and Angus
PW: The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol
Hepatol. 13:412–425. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rosa CGS, Colares JR, da Fonseca SRB,
Martins GDS, Miguel FM, Dias AS, Marroni CA, Picada JN, Lehmann M
and Marroni NAP: Sarcopenia, oxidative stress and inflammatory
process in muscle of cirrhotic rats-action of melatonin and
physical exercise. Exp Mol Pathol. 121:1046622021. View Article : Google Scholar
|
|
41
|
Thomsen KL, Nielsen SS, Grønbiek H,
Flyvbjerg A and Vilstrup H: Effects of lipopolysaccharide endotoxin
on the insulin-like growth factor I system in rats with cirrhosis.
In Vivo. 22:655–661. 2008.
|
|
42
|
Fang WY, Tseng YT, Lee TY, Fu YC, Chang
WH, Lo WW, Lin CL and Lo YC: Triptolide prevents LPS-induced
skeletal muscle atrophy via inhibiting NF-κB/TNF-α and regulating
protein synthesis/degradation pathway. Br J Pharmacol.
178:2998–3016. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sawicka AK, Hartmane D, Lipinska P,
Wojtowicz E, Lysiak-Szydlowska W and Olek RA: l-Carnitine
supplementation in older women. A pilot study on aging skeletal
muscle mass and function. Nutrients. 10:2552018. View Article : Google Scholar :
|
|
44
|
Keller J, Couturier A, Haferkamp M, Most E
and Eder K: Supplementation of carnitine leads to an activation of
the IGF-1/PI3K/Akt signalling pathway and down regulates the E3
ligase MuRF1 in skeletal muscle of rats. Nutr Metab (Lond).
10:282013. View Article : Google Scholar
|
|
45
|
Patel VC, Lee S, McPhail MJW, Da Silva K,
Guilly S, Zamalloa A, Witherden E, Støy S, Manakkat Vijay GK, Pons
N, et al: Rifaximin-α reduces gut-derived inflammation and mucin
degradation in cirrhosis and encephalopathy: RIFSYS randomised
controlled trial. J Hepatol. 76:332–342. 2022. View Article : Google Scholar
|
|
46
|
Kitagawa R, Kon K, Uchiyama A, Arai K,
Yamashina S, Kuwahara-Arai K, Kirikae T, Ueno T and Ikejima K:
Rifaximin prevents ethanol-induced liver injury in obese
KK-Ay mice through modulation of small intestinal
microbiota signature. Am J Physiol Gastrointest Liver Physiol.
317:G707–G715. 2019. View Article : Google Scholar
|
|
47
|
Cellai L, Colosimo M, Marchi E, Venturini
AP and Zanolo G: Rifaximin (L/105), a new topical intestinal
antibiotic: Pharmacokinetic study after single oral administration
of 3H-rifaximin to rats. Chemioterapia. 3:373–377. 1984.PubMed/NCBI
|
